560 followers
Post hoc analysis of 4 Phase 3 trials in C&A with ADHD: Significant improvements observed in ADHD-related functional impairments and reduction in inattention and hyperactivity/impulsivity symptoms was observed with viloxazine ER 100-400 mg/day vs. pla